Angion Biomedica Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANGN research report →
Range $1.5 – $1.5
Price Chart
About the company
Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs.
- CEO
- Jay R. Venkatesan
- IPO
- 2021
- Employees
- 3
- HQ
- Uniondale, NY, US
Get TickerSpark's AI analysis on ANGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $30.11M
- P/E
- -0.47
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 2.42
- EV/EBITDA
- -0.42
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1266.43%
- ROIC
- -163.43%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-37,714,000
- Net Income
- $-39,571,000+23.8%
- EPS
- $-2.58+39.3%
- OCF Growth
- +0.3%
- FCF Growth
- +0.5%
- 52W High
- $20.40
- 52W Low
- $1.00
- 50D MA
- $7.17
- 200D MA
- $8.11
- Beta
- 0.60
- RSI (14)
- 72
- Avg Volume
- 9.77K
No earnings-call transcripts are available for ANGN yet.
- Free Float
- 69.4%
- Shares Outstanding
- 30.11M
- Float Shares
- 20.90M
of shares held by institutions
30 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Amalgamated Financial Corp. | 3.73K | ▲ 3.73K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 28, 23 | Nissenson Allen | other | 4,100 |
| Dec 28, 23 | Chudnovsky Yekaterina | other | 4,100 |
| Dec 28, 23 | WILSON KAREN J | other | 4,100 |
| Dec 28, 23 | ADAMS JULIAN | other | 4,100 |
| Dec 28, 23 | Venkatesan Jay | other | 4,100 |
| Dec 28, 23 | Ashe Carol Gail | other | 4,100 |
| Dec 28, 23 | RUFFOLO ROBERT R | other | 4,100 |
| Dec 22, 23 | Chudnovsky Yekaterina | buy | 1,213,000 |
| Jun 1, 23 | Chudnovsky Yekaterina | other | 0 |
| Jun 1, 23 | Chudnovsky Yekaterina | other | 4,525 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANGN coverage
Recent articles, reports, and earnings notes.
No research on ANGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANGN report →Angion (ANGN) Down on Merger Agreement With Private Biotech
zacks.com · Jan 18
New Strong Buy Stocks for November 16th
zacks.com · Nov 16
New Strong Buy Stocks for October 25th
zacks.com · Oct 25
Angion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read Why
benzinga.com · Jun 30
What to Know About Buying Penny Stocks on June 1st
pennystocks.com · Jun 1
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
zacks.com · May 11
Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021
zacks.com · Dec 13
Angion to Present Multiple Posters at Kidney Week 2021
globenewswire.com · Oct 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.